ConductScience.org, home

Paper43870

Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.

Dreyfuss J and 6 others. J Clin Pharmacol, 1979. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients. Papers, record 43870. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/43870

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.
PubMed
Journal
J Clin Pharmacol
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
2.91
iCite
Revised in PubMed
2019-08-23
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dreyfuss JJ
2Griffith DLD L
3Singhvi SMS M
4Shaw JMJ M
5Ross JJ JrJ J
6Vukovich RAR A
7Willard DAD A

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic beta-AntagonistsMajor topic
HypertensionMajor topic
PropanolaminesMajor topic
Biotransformation
Drug Administration Schedule
Humans
Intestinal Absorption
Kinetics
Middle Aged
Time Factors

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
41686841Effects of matcha green tea on the pharmacokinetics of nadolol in rats.PLoS One2026https://conductscience.org/library/papers/41686841PubMed
38399480A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38399480PubMed
34112223Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.Crit Care2021https://conductscience.org/library/papers/34112223PubMed
11422018Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.Br J Clin Pharmacol2001https://conductscience.org/library/papers/11422018PubMed
8842054Bioequivalence of a highly variable drug: an experience with nadolol.Pharm Res1996https://conductscience.org/library/papers/8842054PubMed
8834196Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.J Pharmacokinet Biopharm1995https://conductscience.org/library/papers/8834196PubMed
6714285Pharmacokinetics of nadolol in healthy subjects.Eur J Clin Pharmacol1984https://conductscience.org/library/papers/6714285PubMed
6124268Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6124268PubMed
6124267Nadolol in thyrotoxicosis.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6124267PubMed
6117304Nadolol in human serum and breast milk.Br J Clin Pharmacol1981https://conductscience.org/library/papers/6117304PubMed
6105067Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.Drugs1980https://conductscience.org/library/papers/6105067PubMed
3987783Nadolol in combination with indapamide and xipamide in resistant hypertensives.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/3987783PubMed
3203065Penetration of nadolol into aqueous humour after a single oral dose.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3203065PubMed
2235896Comparison of single-dose and steady-state nadolol plasma concentrations.Pharm Res1990https://conductscience.org/library/papers/2235896PubMed
1676675A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.Eur J Clin Pharmacol1991https://conductscience.org/library/papers/1676675PubMed
1653143The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.Eur J Clin Pharmacol1991https://conductscience.org/library/papers/1653143PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/43870

GET https://conductscience.org/api/papers/v1/43870/authors